A Quick Introduction to DrugTimes

Thank?you?very much for this precious opportunity! We are much delighted to present a quick introduction to DrugTimes.

DrugTimes is a brand our team has been working on over the past years. Our goal is focus on R&D of innovative drugs, compile valuable industry information, share, communicate and collaborate, finally build a healthy world all together.

As?the founder of DrugTimes, Dr. Jinsong Guo got his PhD degree from Columbia University and then did postdoc research work for 7 years in total, working on the total synthesis of anticancer drug Trabectedin. Then he joined US Merck or MSD as a senior research scientist, working on process chemistry. He also had medicinal chemistry experience?in Scion Pharmaceutical, a biotech in Boston. The compound designed by him was nominated as PCC. After coming back to China, Dr. Guo used to work at WuXi AppTec in different roles, including team management, program management and business development. His biotech experience in China was gained at Haihe Biopharma, where he founded the BD Department and got involved in one successful licensing deal. On January 1st?2019, Dr. Guo started to work on DrugTimes full time. Currently he is also the co-president and secretary general of Alliance of New Drug Development for Liver Diseases, an editorial member of two prestigious journals, Progress In Pharmaceutical Sciences, Acta Pharmacologica Sinica.

We have a very young talented and energetic team, which has been?expanding all the time.

Many experts are our columnists, publishing excellent articles on DrugTimes. Their well written?articles drew a lot of attentions.

Many KOLs, founders, experts from leading pharma and biotech companies kindly provided strong support to us over the past years.

DrugTimes was started back in 2015 as a hobby, grew very fast in the past 8 years, making big progresses each year.

Now DrugTimes Media Matrix is getting more and more mature. Over 200,000 professionals are in our network, last year the traffic is 22M. We can reach professionals not only by articles, but also by videos and live broadcasting, not only in China, but also beyond China, not only in Chinese, but also in English.

We have an integrated platform ready, including new media platform, online and offline activities platform, BD platform.

From service perspective, we can?help pharma, biotech and CXO companies on: press release, planning and execution of events, interview of founders or C suite leaders, third party independent review and comment.

Like introduced previously, we have famous?columnists. They write popular articles in different styles, from different angles.

Dr.?Xie, already 65 articles, about industry trend, cutting-edge science and technology.

Dr. PP, 48 articles, all about famous hot targets, like CD47, KRAS, JAK, BTK…

Dr. Li, 10 articles?about Nobel winners and prestigious institute, published one book recently.

Ms. Yu, 23 articles?about the history and strategy of MNC,?complied into a book, rather popular.

DrugTimes Interview. We have interviewed more than 50 leaders, experts from MNC, local pharma and biotech companies.

We have posted articles to share our own observations and opinions, getting a lot of attentions from the industry.

The second platform is online and offline activities.

Many activities have been successfully completed. This one is about R&D and investment. This one is about non-alcoholic steatohepatitis, or NASH?in short, the first one of its kind in China. As we all know, NASH is a very hot yet difficult field, a lot of failures, the first one will likely be approved by FDA in the near future. After the very successful conference, we formed an alliance, well known in China. A lot of collaborations and activities. Last year, we expanded to cover more liver diseases. We had productive collaborations from experts from the USA, who used to work at FDA for many years.

The CMC conferences got strong support from Porton, a leading CDMO in China. ~800 attendees. Three sessions have been completed successfully.

This year we focus on high end closed-door meetings, with 20 to 40 C level leaders discussing for 7 hours. Each one will focus on one theme or one field, like CNS diseases, liver diseases.

Well attended and well received!

I?was invited to be the chair of panels or whole event, in Zhangjiang, in Hangzhou, on the cruise, in Shanghai Book Fair.

About our online activities. ~180 webinars and live broadcasts have been carried out, with thousands of attendees.

Many companies, including MNC, biotech, CXO and law firms had dedicated programs on our platform.

For 2023, we launched new initiatives, like DrugTimes Workshop, to train young talents from BD, clinical trial and R&D perspectives.?3 sessions have bee completed. We are planning the fourth one now.

The third one is BD platform for licensing, M&A and investment.

We have completed several deals, almost one deal a year, the total value of the deals is over 300M USD, the biggest deal is over 200M USD in value.

Along the way, we have accumulated a lot of experiences and come up with an efficient and effective process, SOP.

We would like to take full advantage of our resources, experiences, traffic, etc. to contribute to the smooth and successful communications and collaborations between two excellent companies.

Currently we have over 30 active projects in the pipeline, trying best to have them closed as many as possible.

If you are looking for quality partners for your promising projects, please feel free to contact us at [email protected]. Our official website in Chinese is https://www.drugtimes.cn. Our English website will be launched in the near future.

Thank you very much!